Study of CAD-1883 for Spinocerebellar Ataxia
Withdrawn before enrolling · Phase 2 · Has a placebo group
Conditions studied: Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10, Spinocerebellar Ataxia Type 17, ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1
In brief
This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of Spinocerebellar Ataxia (SCA). This study offers the opportunity to understand the safety, tolerability, and efficacy of CAD-1883 in the SCA patient population.
Key facts
- Study ID
- NCT04301284
- Run by
- Cadent Therapeutics
- People needed
- 0
- Starts
- 2021-06-01
- Expected to finish
- 2022-12-01
- Last updated by the study team
- 2021-04-08
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Collaborative Neuroscience Network — Long Beach, California, United States
- UCLA Medical Center — Los Angeles, California, United States
- University of Colorado — Aurora, Colorado, United States
- University of Florida — Gainesville, Florida, United States
- University of South Florida: Ataxia Research Center — Tampa, Florida, United States
- Houston Methodist Research Institute — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.